Taysha Gene Therapies (TSHA) Stock Forecast, Price Target & Predictions
TSHA Stock Forecast
Taysha Gene Therapies stock forecast is as follows: an average price target of $18.67 (represents a 780.66% upside from TSHA’s last price of $2.12) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
TSHA Price Target
The average price target for Taysha Gene Therapies (TSHA) is $18.67 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $44.00 to $5.00. This represents a potential 780.66% upside from TSHA's last price of $2.12.
TSHA Analyst Ratings
According to 8 Wall Street analysts, Taysha Gene Therapies's rating consensus is 'Buy'. The analyst rating breakdown for TSHA stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Taysha Gene Therapies Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 14, 2024 | Keith Tapper | BMO Capital | $5.00 | $2.31 | 116.45% | 135.85% |
| Jul 01, 2024 | Christopher Raymond | Piper Sandler | $7.00 | $2.24 | 212.50% | 230.19% |
| May 14, 2024 | Eun Yang | Jefferies | $8.00 | $2.40 | 233.33% | 277.36% |
| Apr 09, 2024 | Christopher Raymond | Raymond James | $9.00 | $2.68 | 235.82% | 324.53% |
| Feb 01, 2023 | - | Jefferies | $1.50 | $1.64 | -8.54% | -29.25% |
| Oct 19, 2021 | Matthew Harrison | Morgan Stanley | $39.00 | $17.63 | 121.21% | 1739.62% |
| May 19, 2021 | Kristen Kluska | Cantor Fitzgerald | $44.00 | $21.78 | 102.02% | 1975.47% |
The latest Taysha Gene Therapies stock forecast, released on Aug 14, 2024 by Keith Tapper from BMO Capital, set a price target of $5.00, which represents a 116.45% increase from the stock price at the time of the forecast ($2.31), and a 135.85% increase from TSHA last price ($2.12).
Taysha Gene Therapies Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $7.25 |
| Last Closing Price | $2.12 | $2.12 | $2.12 |
| Upside/Downside | -100.00% | -100.00% | 241.98% |
In the current month, the average price target of Taysha Gene Therapies stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Taysha Gene Therapies's last price of $2.12. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 14, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Jul 23, 2024 | Needham | Underperform | Underperform | Hold |
| Jul 23, 2024 | Piper Sandler | Buy | Buy | Hold |
| Jul 01, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 26, 2024 | BMO Capital | - | Outperform | Initialise |
| May 28, 2024 | Piper Sandler | Market Outperform | Market Outperform | Hold |
| May 28, 2024 | Needham | Underperform | Underperform | Hold |
| May 14, 2024 | Jefferies | - | Buy | Upgrade |
| Apr 30, 2024 | Piper Sandler | Market Outperform | Market Outperform | Hold |
| Apr 30, 2024 | Needham | Underperform | Underperform | Hold |
Taysha Gene Therapies's last stock rating was published by BMO Capital on Aug 14, 2024. The company gave TSHA a "Outperform" rating, the same as its previous rate.
Taysha Gene Therapies Financial Forecast
Taysha Gene Therapies Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.75M | $2.40M | $4.71M | $2.50M |
| Avg Forecast | $2.95M | $2.79M | $2.64M | $2.50M | $1.76M | $1.74M | $1.71M | $1.71M | $2.14M | $1.74M | $2.76M | $2.88M | $2.95M | $2.33M | $2.40M | $2.25M | $11.25M |
| High Forecast | $3.33M | $3.15M | $2.97M | $2.81M | $1.98M | $1.96M | $1.92M | $1.95M | $2.37M | $1.74M | $2.76M | $2.88M | $3.32M | $2.33M | $2.70M | $2.53M | $12.67M |
| Low Forecast | $2.63M | $2.49M | $2.36M | $2.23M | $1.57M | $1.55M | $1.52M | $1.46M | $2.02M | $1.74M | $2.76M | $2.88M | $2.63M | $2.33M | $2.14M | $2.01M | $10.03M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 7 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.03% | 1.00% | 2.09% | 0.22% |
Taysha Gene Therapies's average Quarter revenue forecast for Dec 23 based on 5 analysts is $2.95M, with a low forecast of $2.63M, and a high forecast of $3.32M. TSHA's average Quarter revenue forecast represents a -37.85% decrease compared to the company's last Quarter revenue of $4.75M (Sep 23).
Taysha Gene Therapies EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 7 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-16.25M | $-22.82M | $-15.92M | $-18.51M |
| Avg Forecast | $590.80K | $558.75K | $528.43K | $499.76K | $352.00K | $348.23K | $341.08K | $341.08K | $428.76K | $347.91K | $551.22K | $576.35K | $589.89K | $466.44K | $479.00K | $450.00K | $2.25M |
| High Forecast | $665.14K | $629.06K | $594.92K | $562.64K | $396.29K | $392.05K | $384.00K | $389.07K | $473.90K | $347.95K | $551.23K | $576.37K | $664.11K | $466.47K | $539.27K | $506.62K | $2.53M |
| Low Forecast | $526.90K | $498.31K | $471.27K | $445.70K | $313.92K | $310.56K | $304.19K | $291.80K | $403.94K | $347.86K | $551.21K | $576.32K | $526.08K | $466.42K | $427.19K | $401.32K | $2.01M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -34.84% | -47.63% | -35.37% | -8.23% |
undefined analysts predict TSHA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Taysha Gene Therapies's previous annual EBITDA (undefined) of $NaN.
Taysha Gene Therapies Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 7 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-117.09M | $-24.60M | $-20.06M | $-58.06M |
| Avg Forecast | $-22.07M | $-22.12M | $-21.21M | $-21.27M | $-25.54M | $-25.97M | $-25.08M | $-24.48M | $-24.81M | $-23.23M | $-42.04M | $-28.73M | $-29.50M | $-46.24M | $-83.31M | $-95.52M | $-106.89M |
| High Forecast | $-18.97M | $-19.01M | $-18.23M | $-18.27M | $-21.95M | $-22.32M | $-21.55M | $-21.03M | $-24.40M | $-19.96M | $-36.13M | $-24.69M | $-25.35M | $-39.74M | $-71.59M | $-82.09M | $-91.86M |
| Low Forecast | $-25.68M | $-25.74M | $-24.68M | $-24.74M | $-29.72M | $-30.22M | $-29.18M | $-28.48M | $-25.23M | $-27.03M | $-48.92M | $-33.43M | $-34.33M | $-53.80M | $-96.94M | $-111.15M | $-124.37M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.53% | 0.30% | 0.21% | 0.54% |
Taysha Gene Therapies's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TSHA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Taysha Gene Therapies SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 7 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $8.59M | $5.99M | $8.75M | $7.34M |
| Avg Forecast | $11.74M | $11.11M | $10.50M | $9.93M | $7.00M | $6.92M | $6.78M | $6.78M | $8.52M | $6.92M | $10.96M | $11.46M | $11.73M | $9.27M | $9.52M | $8.94M | $44.72M |
| High Forecast | $13.22M | $12.50M | $11.83M | $11.18M | $7.88M | $7.79M | $7.63M | $7.73M | $9.42M | $6.92M | $10.96M | $11.46M | $13.20M | $9.27M | $10.72M | $10.07M | $50.35M |
| Low Forecast | $10.47M | $9.90M | $9.37M | $8.86M | $6.24M | $6.17M | $6.05M | $5.80M | $8.03M | $6.91M | $10.96M | $11.46M | $10.46M | $9.27M | $8.49M | $7.98M | $39.89M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | 0.63% | 0.98% | 0.16% |
Taysha Gene Therapies's average Quarter SG&A projection for Dec 23 is $11.73M, based on 5 Wall Street analysts, with a range of $10.46M to $13.20M. The forecast indicates a 36.51% rise compared to TSHA last annual SG&A of $8.59M (Sep 23).
Taysha Gene Therapies EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 7 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.38 | $-0.32 | $-1.03 |
| Avg Forecast | $-0.08 | $-0.08 | $-0.08 | $-0.08 | $-0.10 | $-0.10 | $-0.09 | $-0.09 | $-0.09 | $-0.09 | $-0.16 | $-0.11 | $-0.11 | $-0.17 | $-0.31 | $-0.36 | $-0.40 |
| High Forecast | $-0.07 | $-0.07 | $-0.07 | $-0.07 | $-0.08 | $-0.08 | $-0.08 | $-0.08 | $-0.09 | $-0.07 | $-0.13 | $-0.09 | $-0.09 | $-0.15 | $-0.27 | $-0.31 | $-0.34 |
| Low Forecast | $-0.10 | $-0.10 | $-0.09 | $-0.09 | $-0.11 | $-0.11 | $-0.11 | $-0.11 | $-0.09 | $-0.10 | $-0.18 | $-0.12 | $-0.13 | $-0.20 | $-0.36 | $-0.42 | $-0.46 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.01% | 1.22% | 0.90% | 2.58% |
According to undefined Wall Street analysts, Taysha Gene Therapies's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TSHA previous annual EPS of $NaN (undefined).
Taysha Gene Therapies Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| STTK | Shattuck Labs | $1.14 | $12.00 | 952.63% | Hold |
| XFOR | X4 Pharmaceuticals | $0.37 | $3.67 | 891.89% | Buy |
| TSHA | Taysha Gene Therapies | $2.12 | $18.67 | 780.66% | Buy |
| PRLD | Prelude Therapeutics | $0.96 | $6.25 | 551.04% | Sell |
| CABA | Cabaletta Bio | $2.54 | $16.33 | 542.91% | Buy |
| GOSS | Gossamer Bio | $0.71 | $3.75 | 428.17% | Buy |
| INZY | Inozyme Pharma | $2.81 | $14.67 | 422.06% | Buy |
| BMEA | Biomea Fusion | $6.42 | $22.75 | 254.36% | Buy |
| CCCC | C4 Therapeutics | $4.15 | $13.50 | 225.30% | Buy |
| LRMR | Larimar Therapeutics | $6.38 | $20.33 | 218.65% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.52 | $38.80 | 186.98% | Buy |
| STOK | Stoke Therapeutics | $11.61 | $30.60 | 163.57% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| TERN | Terns Pharmaceuticals | $5.91 | $14.25 | 141.12% | Buy |
| AKRO | Akero Therapeutics | $31.03 | $46.00 | 48.24% | Buy |
| HOOK | HOOKIPA Pharma | $2.79 | $3.00 | 7.53% | Buy |
| ALEC | Alector | $3.85 | $4.00 | 3.90% | Buy |